Skip to main content
. 2022 Aug 10;8(8):1145–1158. doi: 10.1021/acscentsci.2c00598

Figure 4.

Figure 4

Antimicrobial activity of fabimycin against clinical isolates. (A) The susceptibility of clinical isolates (Gram-negative species and S. aureus) to fabimycin, Debio-1452-NH3, and Debio-1452. MICs performed in biological triplicate. (B) Further exploration of the breadth of fabimycin’s antibacterial activity against diverse clinical isolate panels of K. pneumoniae and A. baumannii, as compared to levofloxacin. MICs performed in biological duplicate.